- CureToday.com
- OncLive.com
- TargetedOnc.com
- CancerNetwork.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Peter Schmid, MD | Authors
Articles
Dr. Schmid Discusses the KEYNOTE-522 Trial
October 16, 2019
CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.
Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders
April 07, 2017
In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.